Media headlines about T2 Biosystems (NASDAQ:TTOO) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. T2 Biosystems earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the medical equipment provider an impact score of 45.8423177776759 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- T2 Biosystems to Present at the 17th Annual Needham Healthcare … – Nasdaq (nasdaq.com)
- T2 Biosystems, Inc. (TTOO) – Technical Deep insight – Wall Street Morning (wallstreetmorning.com)
- T2 Biosystems to Present at the 17th Annual Needham Healthcare Conference – The News Reports (thenewsreports.com)
- T2 Biosystems to Present at the 17th Annual Needham Healthcare … – GlobeNewswire (press release) (globenewswire.com)
- T2 Biosystems (TTOO) Raised to Sell at ValuEngine (americanbankingnews.com)
TTOO has been the subject of several recent analyst reports. ValuEngine upgraded shares of T2 Biosystems from a “strong sell” rating to a “sell” rating in a research report on Monday. HC Wainwright set a $8.00 price target on shares of T2 Biosystems and gave the company a “buy” rating in a research report on Monday, February 12th. Goldman Sachs began coverage on shares of T2 Biosystems in a research report on Monday, January 29th. They issued a “neutral” rating and a $5.20 price target for the company. Finally, Zacks Investment Research downgraded shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. T2 Biosystems has a consensus rating of “Hold” and an average target price of $5.66.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.